Latest Insider Transactions at Incyte Corp (INCY)
This section provides a real-time view of insider transactions for Incyte Corp (INCY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of INCYTE CORP to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of INCYTE CORP's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 19
2025
|
Thomas Tray Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,774
-10.77%
|
$277,400
$100.0 P/Share
|
|
Dec 19
2025
|
Thomas Tray Principal Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,774
+5.23%
|
$263,530
$95.76 P/Share
|
|
Dec 18
2025
|
Thomas Tray Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
600
-2.55%
|
$58,800
$98.25 P/Share
|
|
Dec 17
2025
|
Michael James Morrissey EVP, Head of Tech. Operations |
SELL
Open market or private sale
|
Direct |
4,323
-13.58%
|
$419,331
$97.26 P/Share
|
|
Dec 16
2025
|
Michael James Morrissey EVP, Head of Tech. Operations |
SELL
Open market or private sale
|
Direct |
54,008
-31.76%
|
$5,238,776
$97.36 P/Share
|
|
Dec 11
2025
|
Patrick A Mayes EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
255
-0.42%
|
$23,970
$94.94 P/Share
|
|
Dec 10
2025
|
Patrick A Mayes EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,553
-8.44%
|
$527,535
$95.58 P/Share
|
|
Dec 08
2025
|
Herve Hoppenot Director |
SELL
Payment of exercise price or tax liability
|
Direct |
2,843
-0.86%
|
$272,928
$96.7 P/Share
|
|
Dec 02
2025
|
Steven H Stein EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
20,105
-24.15%
|
$2,050,710
$102.51 P/Share
|
|
Dec 01
2025
|
Richard A. Hoffman EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
9,466
+50.0%
|
-
|
|
Dec 01
2025
|
Michael James Morrissey EVP, Head of Tech. Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
326
-0.38%
|
$33,252
$102.04 P/Share
|
|
Dec 01
2025
|
Steven H Stein EVP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
17,093
-17.04%
|
$1,743,486
$102.04 P/Share
|
|
Dec 01
2025
|
Steven H Stein EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,559
-2.49%
|
$261,018
$102.96 P/Share
|
|
Nov 24
2025
|
Thomas Tray Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
600
-2.48%
|
$61,800
$103.0 P/Share
|
|
Nov 21
2025
|
Thomas Tray Principal Accounting Officer |
SELL
Open market or private sale
|
Direct |
169
-0.69%
|
$17,238
$102.0 P/Share
|
|
Nov 17
2025
|
Sheila A. Denton EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
278
-1.04%
|
$28,912
$104.36 P/Share
|
|
Nov 17
2025
|
Sheila A. Denton EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
278
+1.02%
|
$17,792
$64.25 P/Share
|
|
Nov 10
2025
|
Herve Hoppenot Director |
SELL
Open market or private sale
|
Direct |
187,500
-36.26%
|
$19,687,500
$105.46 P/Share
|
|
Nov 05
2025
|
Steven H Stein EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,233
-4.84%
|
$533,766
$102.2 P/Share
|
|
Nov 05
2025
|
Steven H Stein EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,233
+1.6%
|
$476,203
$91.78 P/Share
|
|
Nov 04
2025
|
Sheila A. Denton EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
598
-2.2%
|
$60,398
$101.36 P/Share
|
|
Nov 04
2025
|
Sheila A. Denton EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
598
+2.15%
|
$34,684
$58.06 P/Share
|
|
Nov 03
2025
|
Lee Heeson EVP, Head of Incyte Intl |
SELL
Open market or private sale
|
Direct |
3,074
-9.51%
|
$288,956
$94.02 P/Share
|
|
Oct 15
2025
|
Sheila A. Denton EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
277
-1.03%
|
$23,545
$85.13 P/Share
|
|
Oct 15
2025
|
Sheila A. Denton EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
277
+1.02%
|
$17,728
$64.25 P/Share
|
|
Oct 03
2025
|
Sheila A. Denton EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
3,501
-11.64%
|
$297,585
$85.54 P/Share
|
|
Oct 02
2025
|
Sheila A. Denton EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
3,130
-9.43%
|
$269,180
$86.28 P/Share
|
|
Oct 02
2025
|
Sheila A. Denton EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
599
-1.77%
|
$52,113
$87.65 P/Share
|
|
Oct 02
2025
|
Sheila A. Denton EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
599
+1.74%
|
$34,742
$58.06 P/Share
|
|
Oct 01
2025
|
Lee Heeson EVP, Head of Incyte Intl |
SELL
Payment of exercise price or tax liability
|
Direct |
463
-1.41%
|
$39,818
$86.7 P/Share
|
|
Oct 01
2025
|
Patrick A Mayes EVP & Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,569
-2.33%
|
$134,934
$86.7 P/Share
|
|
Sep 30
2025
|
Baker Bros. Advisors LP |
BUY
Grant, award, or other acquisition
|
Indirect |
776
+0.01%
|
-
|
|
Sep 30
2025
|
Edmund Harrigan Director |
BUY
Grant, award, or other acquisition
|
Direct |
289
+1.38%
|
$24,276
$84.81 P/Share
|
|
Sep 30
2025
|
Paul J Clancy Director |
BUY
Grant, award, or other acquisition
|
Direct |
285
+1.21%
|
$23,940
$84.81 P/Share
|
|
Sep 22
2025
|
David H Gardner EVP, Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,429
+50.0%
|
-
|
|
Sep 16
2025
|
Sheila A. Denton EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
278
-0.83%
|
$23,074
$83.15 P/Share
|
|
Sep 16
2025
|
Sheila A. Denton EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
278
+0.82%
|
$17,792
$64.25 P/Share
|
|
Sep 02
2025
|
Sheila A. Denton EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
598
-1.77%
|
$50,232
$84.97 P/Share
|
|
Sep 02
2025
|
Sheila A. Denton EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
598
+1.74%
|
$34,684
$58.06 P/Share
|
|
Aug 25
2025
|
Ramitpal K Basi EVP, Human Resources |
BUY
Grant, award, or other acquisition
|
Direct |
6,506
+50.0%
|
-
|
|
Aug 15
2025
|
Sheila A. Denton EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
277
-0.83%
|
$23,822
$86.81 P/Share
|
|
Aug 15
2025
|
Sheila A. Denton EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
277
+0.82%
|
$17,728
$64.25 P/Share
|
|
Aug 04
2025
|
Sheila A. Denton EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
598
-1.77%
|
$44,850
$75.77 P/Share
|
|
Aug 04
2025
|
Sheila A. Denton EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
598
+1.74%
|
$34,684
$58.06 P/Share
|
|
Jul 21
2025
|
Steven H Stein EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
3,706
-3.48%
|
$248,302
$67.94 P/Share
|
|
Jul 16
2025
|
Sheila A. Denton EVP & General Counsel |
SELL
Open market or private sale
|
Direct |
785
-2.31%
|
$53,380
$68.36 P/Share
|
|
Jul 16
2025
|
Vijay K Iyengar EVP, GMAPPS |
SELL
Open market or private sale
|
Direct |
983
-2.37%
|
$66,844
$68.36 P/Share
|
|
Jul 16
2025
|
Barry P Flannelly EVP & General Manager US |
SELL
Open market or private sale
|
Direct |
1,340
-3.67%
|
$91,120
$68.36 P/Share
|
|
Jul 15
2025
|
Sheila A. Denton EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
8,184
+19.41%
|
-
|
|
Jul 15
2025
|
Sheila A. Denton EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
703
-2.65%
|
$47,804
$68.25 P/Share
|